Table 1_Gut health and microbiome modulation by the heat-killed postbiotic beLP1® in adults with excess weight: a randomized, placebo-controlled trial.docx

The primary endpoint was change in gastrointestinal symptoms via the GSRS, secondary endpoints included the Perceived Stress Scale (PSS), the Digestion-associated Quality of Life Questionnaire (DQLQ), Tumor Necrosis Factor-alpha (TNF-α), lipid parameters, Dual-Energy X-ray Absorptiometry (DEXA), and gut microbiome diversity by metagenomic Next-Generation Sequencing (NGS).</p>Results<p>Compared to placebo, beLP1^® significantly reduced total Gastrointestinal Symptom Rating Scale (GSRS) scores at Day 42 (p = 0.0215) and Day 84 (p = 0.0394), with prominent improvements in abdominal pain (p = 0.0205) and dyspeptic syndrome (p = 0.0303) domains.

Significant reductions in perceived stress (p = 0.0004) and improvements in digestion-associated quality of life (p = 0.0008) were concurrently achieved. Metagenomic analysis revealed a favorable modulation of the gut microbiota, characterized by an enrichment of several short-chain fatty acid-producing bacteria and a significant reduction in multiple opportunistic pathogens. No significant changes occurred in serum TNF-α, lipid profiles, or DEXA body composition metrics.</p>Conclusion<p>Overall, beLP1^® safely and progressively alleviates GI symptoms, reduces stress, and optimizes microbiome composition in adults with excess weight.

ClinicalTrials.gov: NCT05820737.</p>Clinical trial registration<p>clinicaltrials.gov/study/NCT05820737?cond=NCT05820, identifier NCT05820737.</p>